Introduction
============

Several studies showed that even moderate weight loss improves metabolic complications of obesity.^[@bib1],\ [@bib2]^ This may be due to a preferential loss of visceral fat compared with subcutaneous^[@bib3],\ [@bib4]^ or may also be due to a reduction in the ectopic fat content.^[@bib5],\ [@bib6],\ [@bib7],\ [@bib8],\ [@bib9]^ In fact, it has been demonstrated that ectopic fat deposition (i.e., liver, pancreas and muscle fat infiltration) significantly contributes to insulin resistance and metabolic alterations observed in obese subjects.^[@bib6],\ [@bib7]^ Recently, in a murine model it has been shown that impairment of glucose homeostasis and insulin resistance are associated with hepatosteatosis^[@bib9]^ and triglyceride overaccumulation in the pancreas,^[@bib10]^ consequent to long-term high-fat feeding. Using computed tomography at the midthigh level, a significant decrease in muscle lipid content after moderate weight loss has been observed in obese sedentary subjects.^[@bib5],\ [@bib6],\ [@bib8]^

Using magnetic resonance, Colles *et al.*^[@bib11]^ observed a significant decline in liver volume, a proxy of liver fat infiltration, after a mean weight loss of 10% in obese subjects. In eight obese subjects with type 2 diabetes, Peterson *et al.*^[@bib12]^ observed that a weight loss of 8 kg normalized fasting glucose and that this improvement was associated with an 81% decline of intrahepatic lipid content.

To the best of our knowledge, no studies have evaluated the effect of weight loss on pancreas lipid content in obese people or the possible contribution of its decrease to the metabolic improvement observed after weight loss. Furthermore, no studies compared the relative simultaneous decline in liver and pancreas ectopic fat deposition after weight loss.

The aim of this study was to compare the effect of weight loss on visceral and subcutaneous abdominal fat and on liver and pancreas fat content. A further aim was to test the combined and separate effects of these simultaneous declines on metabolic improvement. Magnetic resonance, considered the gold standard for assessment of body composition,^[@bib13]^ was used to quantify visceral and subcutaneous adipose tissue as well as liver and pancreas lipid content before and after weight loss.

Materials and methods
=====================

Subjects
--------

A total of 24 subjects (13 men and 11 women) with mean age 46.7±14.3 years and mean body mass index (BMI) 35.4±4.5 kg m^−2^, were included in the study. All subjects were in good general health, as determined by a complete medical history and physical examination, as well as a normal blood count, chemical screening battery and urine analysis except for obesity, hypercholesterolemia (42.8%), hypertension (35.7%). No patients had previously diagnosed diabetes according to American Diabetes Association,^[@bib14]^ 21.4% were smokers. Subjects with fasting plasma glucose ⩾7 m[M]{.smallcaps} l^−1^ (two men and one woman) were excluded from the study as well as subjects with daily alcohol consumption, \>30 g for men and \>20 g for women.^[@bib15]^ All women were post-menopausal and not on hormonal replacement therapy. None of the participants was regularly engaged in physical activity or changed his physical activity level during the study. All participants gave their informed consent and the experimental protocol was approved by the Ethical Committee of our University.

Anthropometric measurements
---------------------------

With the subjects wearing light indoor clothes and no shoes, body weight was measured to the nearest 0.1 kg. (Salus scale, Milan, Italy), and height to the nearest 0.5 cm using a stadiometer (Salus stadiometer). BMI was calculated as body weight adjusted by stature squared (kg m^−2^). Waist circumference was obtained with a measuring tape as the minimum circumference between the xyphoid process and the umbilicus.

Body composition assessment
---------------------------

Body composition was measured using dual-energy X-ray absorptiometry (Hologic QDR 4500, Waltham, MA, USA) array beam System Software Version 11.1.

The characteristics and physical concepts of dual-energy X-ray absorptiometry measurement have been described elsewhere.^[@bib16]^ Daily quality-assurance tests were performed according to the manufacturer\'s directions. All scans were subsequently analyzed by a single trained investigator. Total body fat was expressed in kg (fat mass) and as a percentage of body weight (fat mass %).

Magnetic resonance data acquisition
-----------------------------------

MRI (magnetic resonance imaging) was performed with a 1.5 T magnet (Symphony, Siemens Medical Systems, Erlangen, Germany) and two body phased-array coils. The imaging protocol included an axial T1-weighted dual-phase gradient-echo sequence (repetition time ms/echo time ms, 96/2.33 (opposed phase), 96/4.85 (in phase); flip angle 70° matrix 320 × 320; field of view 500 cm) of the upper abdomen and an axial T1-weighted gradient-echo sequence (TR 90; TE 3.46; flip angle 70° matrix 256 × 256; field of view 500 cm) from L3 to L5. APR and GAZ rated the quality of all MR images on a scale of 1 to 5 (5 being optimal signal to noise ratio, 1 being unreadable) as previously described.^[@bib17]^ The average MR quality was 4.1 (ranging from 3 to 5).

Abdominal fat evaluation
------------------------

All images were analyzed using Sliceomatic image analysis software (version 4.2, Tomovision, Montreal, Canada) and a single reader measured visceral adipose tissue (AT) and subcutaneous AT on a single slice at L4--L5 for men and women, as previously described.^[@bib13]^

Abdominal subcutaneous AT area was defined as the area of adipose tissue between the skin and the outermost aspect of the abdominal muscle wall. All the adipose tissue pixels within the abdominal cavity between the innermost aspect of the abdominal and oblique wall musculature and the anterior aspect of the vertebral body were considered visceral abdominal AT. Interclass correlations for intra-reader comparisons in a subgroup of 20 subjects were 0.996 for subcutaneous AT, 0.993 for visceral AT.

Ectopic fat infiltration evaluation
-----------------------------------

MR images were reviewed on a commercially available workstation (Leonardo, Siemens Medical Systems) by a single reader who was unaware of laboratory and clinical results.

The technique used to measure SI (signal intensity) values from regions of interest (ROIs) in the liver and spleen and to calculate the relative SI losses of the liver and the other organs was based on methods previously described for the liver.^[@bib18]^ The percentage of relative SI loss on opposed-phase MR images was considered to be a reasonable measurement of liver fat on the basis of the known effect of fat on SI values. The SI values of the liver and spleen were recorded on in- and opposed-phase T1-weighted MR images by positioning circular ROIs at anatomically matched locations on paired sequences, avoiding visible vessels, abnormalities and artefacts. Three circular ROIs were positioned in the liver (left lobe, upper right lobe and lower right lobe), three in the pancreas (head, body and tail, avoiding the main pancreatic duct), one each in the psoas muscles. The s.d. of the SI measurements within each ROI was kept to less than 10%. The SI of the spleen was similarly measured by positioning two circular ROIs in the splenic parenchyma. Size of the ROI was variable in the different organs: 1--2 cm diameter for the liver and spleen, equal or smaller for the pancreas. When more than one ROI was positioned in an organ, a mean SI was calculated to account for signal heterogeneity.

Liver fat was estimated on opposed-phase MR images as the percentage of relative SI loss of the liver on opposed-phase images with a previously used formula^[@bib18]^ where L~in~ is in-phase mean liver SI, S~in~ is mean in-phase spleen SI, L~op~ is mean opposed-phase liver SI and S~op~ is mean opposed-phase spleen SI.

Similar formulas were used to calculate the amount of fat in the pancreas according to previous reports.^[@bib17],\ [@bib19],\ [@bib20]^ The grading system for liver steatosis was based on that used in earlier studies:^[@bib21],\ [@bib22]^ grade 0 corresponding to less than 5% steatosis; grade 1 to 6--33% steatosis; grade 2 to 34--66% steatosis; and grade 3 to greater than 66% steatosis. The grading system incorporates the accepted normal value of histopathological liver fat, which is less than 5%, and is the standard applied in the clinical assessment of severity of liver steatosis. We calculated the intra- and inter-observer variability of our MRI measurements for pancreatic fat content and liver fat content, which were 8.2% and 9.7% and 7.8% and 8.2%, respectively (as determined in a subset of 20 obese patients).^[@bib17]^

Biochemical analyses
--------------------

Venous blood samples for all metabolic assessments were obtained after overnight fast. Plasma glucose was measured using a glucose analyzer (Beckman Instruments Inc., Palo Alto, CA, USA). The intra-assay coefficient of variation was 1.5%.

Plasma immune-reactive insulin underwent duplicate measurements by double-antibody radioimmunoassay using a commercial kit (Diagnostic Products Corp., Los Angeles, CA, USA). Sensitivity was 6 p[M]{.smallcaps} l^−1^ and the intra-assay coefficient of variation was 4.9%.

Insulin resistance was estimated with the HOMA (homeostasis model assessment of insulin resistance) method.^[@bib23]^

Cholesterol and triglyceride levels were determined using a Technicon Auto analyzer (Technicon Inc., Co, Tarrytown, NY, USA) and dextran-magnesium precipitation was used to separate high-density lipoprotein.

Serum leptin was measured using a specific ELISA kit (DBC-Diagnostic Biochem Canada Inc., London, Canada). Sensitivity was 0.5 ng ml^−1^ and the intra-assay and interassay coefficient of variations were 7.4% and 9.6%, respectively.

Serum adiponectin was measured with a commercially available ELISA kit (B-Bridge International, Inc., Sunnyvale, CA, USA). Sensitivity was 20 pg ml^−1^ and the intra-assay and interassay coefficient of variations were 3.5% and 5.2%, respectively.

Dietary intake
--------------

A trained dietician performed a 7-day dietary recall interview in order to assess the dietary habits of each subject enrolled in the study. A recall grid representing 7 days of the prior week and all possible food-encounter times was used by the dietician. Portion sizes were estimated for foods and fluids by comparing with reference foods and fluids in a booklet of photographs. The interview takes approximately 40 min, on average, for the study subject to complete. The record data were then processed by the dietician using special software to calculate daily intake of energy, protein, fat, carbohydrate and alcohol based on the tables furnished by the Italian National Institute of Nutrition.^[@bib24]^

Hypoenergetic diet
------------------

All the subjects completed a weight-loss program designed to achieve a loss of 7--10% of the initial weight. The caloric restriction was 500 kcal below the resting energy expenditure, as evaluated by indirect calorimetry and multiplied by a physical activity level of 1.4. Each subject received a diet providing 62% carbohydrates, 24% fat, 14% protein and 20 g fiber. The only beverage allowed was water. The subjects underwent monthly clinical and nutritional follow-ups. Dietary compliance was checked by a 24-h recall every 4 weeks during an outpatient visit.

Statistical analyses
--------------------

Results are shown as means±s.d. Log transformations were performed for non-normal variables. Comparisons of anthropometric, metabolic and body-composition variables before and after weight loss were made by using paired *t*-test. Mcnemar test was used to test changes in the prevalence of liver steatosis before and after weight loss. Correlation analyses were used to test associations between variables. Linear regression analyses were used to test the joint effects of changes in liver and pancreas lipid content, as well as changes in leptin, high-sensitivity C-reactive protein (hs-CRP), visceral AT and waist circumference after weight loss on HOMA changes. The level of statistical significance was *P*\<0.05 for all the variables. All statistical analyses were performed using the SPSS statistical package.^[@bib25]^

Results
=======

The flowchart of study participants is shown in [Figure 1](#fig1){ref-type="fig"}. Anthropometric, body composition, fat distribution, hs-CRP, adipokines and metabolic variables before and after weight loss are shown in [Table 1](#tbl1){ref-type="table"}. The mean decrease in body weight was 8.9%. BMI and waist circumference significantly decreased after weight loss (both *P*\<0.001) as well as fat mass and fat mass % (both *P*\<0.001). Visceral, subcutaneous and total abdominal AT significantly decreased (all *P*\<0.001). Among the metabolic variables, glucose, insulin, HOMA, total cholesterol, triglycerides and leptin significantly decreased (all *P*\<0.01), whereas adiponectin did not change. A significant decline was also observed in gamma glutamyl transpeptidase and alanine amino transferase (both *P*\<0.001).

Changes in liver and pancreas lipid content in each of the subjects enrolled in the study expressed as mean±s.d. values are shown in [Figures 2a and b](#fig2){ref-type="fig"}. Liver lipid content significantly decreased, as well as pancreas lipid content (*P*\<0.001 and *P*=0.001, respectively). Interestingly, percent changes in liver lipid content were greater (84.1±3%) than those in pancreas lipid content (42.3±29%), visceral abdominal AT (31.9±15.6%) and subcutaneous abdominal AT (13.6±25.9%).

As far as hepatic steatosis, as assessed by MRI, 75% (18/24) patients showed steatosis at baseline: respectively 50% (12/24) grade 1 steatosis, 12.5% (3/24) grade 2 steatosis and 12.5% (3/24) grade 3 steatosis. After weight loss, the percentage of subjects with steatosis significantly decreased to 12.5% (*P*=0.008) and none of these subjects had grade 2 or 3 steatosis ([Figure 3](#fig3){ref-type="fig"}).

[Table 2](#tbl2){ref-type="table"} shows the correlations between changes in anthropometric variables, body composition, biochemical variables and changes in liver and pancreas lipid content and HOMA index after weight loss.

The loss of liver lipid content was related with the decrease in visceral AT (*r*=0.664, *P*\<0.001), subcutaneous AT (*r*=0.505, *P*=0.012) and hs-CRP (*r*=0.554, *P*=0.005). Pancreas lipid infiltration decrease was related to visceral AT decrement after weight loss (*P*\<0.001). An association between the respective changes in the liver and pancreas lipid content was also observed (*P*=0.033).

HOMA improvement was associated with reduction in waist circumference, visceral and subcutaneous abdominal AT and change in hs-CRP and insulin.

To evaluate independent determinants of insulin resistance improvement, a linear regression analysis was performed considering changes in HOMA index as dependent variable and the variables most closely correlated with it as independent variables. [Table 3](#tbl3){ref-type="table"} shows different models considering gender, changes in liver and pancreas lipid content, visceral AT (or alternatively waist), leptin and hs-CRP as determinants of HOMA improvement.

The proportion of variance explained by gender and change in liver lipid content was 55%. When change in waist was added, 65.3% of variance was explained. When change in hs-CRP was also included in the model, a further increase in the proportion of variance was observed (71.9%) and F-test value decreased to 12.138. Building a model considering gender, changes in liver lipid content, visceral AT and hs-CRP as independent variables, 62.9% of variance in liver lipid content was explained.

A 49.7% and 49.1% of variance was explained, respectively, building models using gender and waist or alternatively gender and visceral AT.

Discussion
==========

Our study shows that a moderate weight loss reduces visceral AT as well as hepatic and pancreatic lipid content. After weight loss, percent changes are greater in liver lipid content than in pancreas lipid content and visceral abdominal AT. Furthermore, insulin resistance, hs-CRP and leptin were significantly reduced after weight loss. Changes in liver lipid content were the best predictors of insulin resistance improvement after weight loss independently of changes in visceral fat distribution, pancreas lipid content, leptin, systemic inflammation as evaluated with hs-CRP and gender.

As expected, in agreement with previous studies,^[@bib4],\ [@bib26]^ after weight loss the amount of visceral abdominal AT loss was higher than that of subcutaneous abdominal AT. Preferential loss of visceral abdominal AT during initial modest weight loss, due to its higher lipolysis response, has been reported.^[@bib26]^

After moderate weight loss, we also observed a significant loss in all ectopic fat compartments in our subjects. The decrease in liver lipid content after weight loss has been previously reported in patients with type 2 diabetes,^[@bib12],\ [@bib27]^ overweight^[@bib28]^ and obese.^[@bib29],\ [@bib30]^

Interestingly, a decline in body fat % of about 3 units (from 36.4 to 33.5, [Table 1](#tbl1){ref-type="table"}), as in our study, has been shown to be associated with a much greater decline in liver lipid content and with a nearly total disappearance of liver steatosis. In fact, in our study sample, 75% of subjects had liver steatosis, as estimated according to Bahl *et al.*^[@bib22]^ by liver SI losses higher than 3%, at the beginning of the study and only 12.5% still had after weight loss, thus suggesting that a moderate weight loss is a landmark treatment for this condition.

To the best of our knowledge, no studies have evaluated changes in pancreas lipid content after weight loss. Our study shows a more than 40% reduction of pancreas lipid content after a moderate weight loss. Pancreas lipid content raises great interest because it has been suggested that fat deposition in and around pancreatic islets could be associated with impaired beta cells function in humans.^[@bib31],\ [@bib32]^ However, its decrease after moderate weight loss, as reported in our subjects, could contribute to the improvement of insulin resistance following weight loss.

Our data support that even moderate weight loss may decrease ectopic fat deposition in both, liver and pancreas, and that the amount of the decline in each compartment may be different. In fact, in our study group, mean changes in liver lipid content were greater than those in pancreas lipid content as well as than in visceral abdominal AT. Our findings of greatest decline in liver lipid content are at least partially in line with those of Colles *et al.*,^[@bib11]^ who demonstrated that intra-hepatic fat was mobilized faster than visceral and subcutaneous fat and with those of others.^[@bib8],\ [@bib12],\ [@bib27],\ [@bib28],\ [@bib29]^ Actually, our results seem to complement and expand these previous findings by also giving information on the effects of weight loss on pancreas lipid content.

Excess liver and pancreas lipid content have been shown to be frequently present in the same patients: Lee *et al.*^[@bib33]^ showed that concurrence of fatty pancreas and fatty liver, as estimated by sonography, was found in 70% of subjects and fatty liver without fatty pancreas just in 2%. However, our findings seem to suggest that dietary restriction may mobilize more ectopic fat stored in the liver than in the pancreas.

It has been recently observed, by using immuno-histochemistry, that fat in human pancreas could be stored in adipocytes between pancreatic cells in addition to vacuoles in pancreatic cells.^[@bib34]^

No similar evidence has been shown in liver where fat is located inside hepatic cells; thus our findings of a higher decline of lipid content in liver than in pancreas could be at least partially explained by the fact that weight loss may easily mobilize triglycerides located inside pancreatic or hepatic cells than those located inside adipocytes between pancreatic cells.

As expected, in line with previous studies, a moderate weight loss improved all metabolic variables.^[@bib2],\ [@bib3],\ [@bib4],\ [@bib6]^ Insulin resistance, as estimated by HOMA index, was significantly improved after weight loss in our subjects.

Insulin resistance could result from the contribution of visceral fat through increased flux of free fatty acids to the liver^[@bib35]^ or by the activity of some adipokines, such as leptin and adiponectin^[@bib36]^ or by intracellular fatty acid metabolism through activation of serine kinase cascade.^[@bib37]^ In agreement with some^[@bib6]^ but not all studies,^[@bib38],\ [@bib39]^ adiponectin levels were not modified by moderate weight loss in our subjects, thus adiponectin changes did not seems to have a major role at least in our study in causing the observed improvement of insulin resistance.

On the contrary, it is possible to hypothesize that the significant changes in liver, pancreatic fat content, visceral AT and leptin, observed after weight loss could be all associated with the improvement in insulin resistance.

To test the joint effects of changes in liver and pancreas lipid content, fat distribution, leptin and hs-CRP after weight loss on HOMA improvement we performed a step-down multiple regression analyses: changes in liver lipid content were independently associated with HOMA improvement.

Changes in liver lipid content together with gender explained in our study 55.4% of the variance of insulin resistance improvement after weight loss, independently of visceral fat and pancreas lipid content decrease. This finding seems to be in line with recent observations that increased fat accumulation in liver is the main determinant of peripheral and hepatic insulin resistance^[@bib40]^ as well as with the findings that early and major decrease in liver fat after weight loss occurs at the same time of normalization of hepatic insulin sensitivity and fall of glucose levels.^[@bib41]^

Some limitations of our study should be recognized. First, the relatively small study sample size. Further, although MR spectroscopy has been used in the majority of studies that evaluated liver lipid content before and after weight loss, we used the MR chemical shift technique. However, high accuracy for the quantification of liver lipid content, validated also against histological determined percentage of fat,^[@bib22]^ and pancreas lipid content^[@bib20]^ has been recently reported for this technique. Moreover, it has been recently shown that in/opposed phase technique is a valid and reliable tool for both, hepatic and pancreatic fat quantification, showing good agreement with fat-selective spectral-spatial gradient-echo imaging^[@bib20],\ [@bib42],\ [@bib43]^ and also with magnetic resonance spectroscopy.^[@bib44]^ MR spectroscopy still lacks general availability in current clinical practice, and the analysis can be performed only on one voxel at a time. On the contrary, MRI scan using T1-weighted gradient-echo in-phase and opposed-phase sequence is a rapid and available technique, already routinely included in MR-imaging protocols for the upper abdomen. Moreover, the analysis can be performed on whole organs, and not on single voxels.

Finally, we only evaluated a surrogate marker of insulin resistance such as HOMA index and then we were not able to evaluate hepatic insulin resistance. Thus, it is possible to speculate that our results could be even more relevant if more sophisticated methods tailored to test hepatic insulin resistance were used.

In conclusion, our data show that a moderate weight loss determines a significant decline in visceral abdominal fat, together with a decline in lipid fat content inside liver and pancreas. After weight loss percent changes are greater in liver than in pancreas lipid content and in visceral abdominal AT. Finally, changes in liver lipid content seem to be the most important predictor of insulin resistance improvement after weight loss. These results have clinical implications showing that even a small weight loss is able to reduce ectopic fat deposition in different splanchnic districts (liver and pancreas) and this reduction is significantly related to relevant metabolic improvements and showed that moderate weight loss is a cornerstone treatment of liver steatosis in obese people.

The research was supported by Italian Minister of Health project 'Pathophysiology, clinical and therapeutical aspects of morbid obesity: a comprehensive approach in the management of the disease and its comorbidities\'.
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###### Anthropometric, body composition, fat distribution, metabolic variables, Hs-CRP and adipokines variables before and after weight loss

  *Variables*                                  *Baseline mean±s.d.* N=*24 (M/F:13/11)*   *After weight loss mean±s.d.* N=*24 (M/F:13/11)*   *Percentage change* (%)   P
  -------------------------------------------- ----------------------------------------- -------------------------------------------------- ------------------------- ---------
  Weight (kg)                                  98.4±15.9                                 89.7±14.8                                          −8.88                     \<0.001
  BMI (kg m^−2^)                               35.4±4.5                                  32.2±4.0                                           −9.04                     \<0.001
  Waist circumference (cm)                     105.4±12.3                                98.6±10.6                                          −6.04                     \<0.001
  Fat mass (kg)                                35.3±6.9                                  29.6±6.1                                           −16.1                     \<0.001
  Fat mass percent (%)                         36.4±6.2                                  33.5±6.4                                           −7.96                     \<0.001
  Fat-free mass (kg)                           63.1±7.9                                  60.1±7.2                                           −4.71                     \<0.001
  Total abdominal AT (cm^2^)                   574.3±154.1                               464.5±135.7                                        −19.1                     \<0.001
  Subcutaneous abdominal AT (cm^2^)            399.9±124.4                               345.5±114.1                                        −13.6                     \<0.001
  Visceral abdominal AT (cm^2^)                174.8±94.7                                118.9±76.3                                         −31.9                     \<0.001
  Liver lipid content (%)                      20.9±25.4                                 3.3±7.5                                            −84.1                     \<0.001
  Pancreas lipid content (%)                   19.7±23.3                                 11.3±14.3                                          −42.3                     =0.001
  Glucose (m[M]{.smallcaps} l^−1^)             5.1±0.6                                   4.9±0.6                                            −0.37                     =0.01
  Insulin (μUI ml^−1^)                         14.9±7.8                                  9.1±4.3                                            −39.1                     \<0.001
  HOMA                                         3.35±1.6                                  1.98±0.9                                           −40.9                     \<0.001
  Total cholesterol (m[M]{.smallcaps} l^−1^)   5.43±1.1                                  4.93±0.8                                           −9.2                      =0.002
  HDL cholesterol (m[M]{.smallcaps} l^−1^)     1.23±0.4                                  1.29±0.4                                           4.8                       =0.06
  Triglycerides (m[M]{.smallcaps} l^−1^)       1.63±0.86                                 1.19±0.52                                          −26.99                    =0.01
  Gamma GT (UI l^−1^)                          27.79±19.8                                19.33±17.00                                        −30.4                     \<0.001
  ALT (UI l^−1^)                               37.25±23.09                               28.46±17.48                                        −23.6                     \<0.001
  Leptin (ng ml^−1^)                           32.95±20.24                               20.88±16.04                                        −36.6                     \<0.001
  Adiponectin (μg dl^−1^)                      15.12±8.58                                15.70±8.90                                         3.8                       =0.316
  Hs-CRP (mg l^−1^)                            5.55±6.28                                 3.48±3.30                                          37.3                      =0.005

Abbreviations: ALT, alanine amino transferase; AT, adipose tissue; BMI, body mass index; Gamma GT, gamma glutamyl transpeptidase; HDL, high-density lipoprotein; HOMA, Homeostasis Model Assessment of insulin resistance; Hs-CRP, high-sensitivity C-reactive protein.

###### Correlations between anthropometric, fat distribution, liver and pancreas lipid content measured with magnetic resonance and biochemical variables changes after weight loss

                        Δ *body Weight*   Δ *body mass index*   Δ *waist circumference*   Δ *visceral abdominal AT*   Δ *subcutaneous abdominal AT*   Δ *liver lipid content*   Δ *pancreas lipid content*
  --------------------- ----------------- --------------------- ------------------------- --------------------------- ------------------------------- ------------------------- ----------------------------
  Δ Insulin             0.56^\*\*^        0.41                  0.53^\*\*^                0.37                        0.24                            0.32                      0.09
  Δ Glucose             0.01              −0.11                 −0.14                     0.22                        0.37                            0.09                      0.26
  Δ HOMA                0.50^\*\*\*^      0.32                  0.63^\*\*^                0.67^\*^                    0.43^\*\*\*^                    0.68^\*^                  0.32
  Δ Total cholesterol   0.29              0.17                  −0.21                     0.06                        −0.02                           −0.22                     −0.07
  Δ HDL cholesterol     −0.04             −0.00                 −0.11                     −0.18                       −0.11                           −0.17                     0.17
  Δ Triglycerides       0.12              −0.06                 0.04                      0.32                        0.14                            0.10                      0.03
  Δ hs-CRP              0.33              0.16                  0.23                      0.54^\*\*^                  0.38                            0.55^\*\*^                0.22
  Δ Adiponectin         −0.10             −0.34                 0.03                      0.33                        −0.03                           0.08                      0.19
  Δ Leptin              0.11              −0.04                 0.02                      −0.13                       0.44^\*\*\*^                    0.09                      0.00

Abbreviations: AT, adipose tissue; HOMA, homeostasis model assessment; hsCRP, high-sensitivity C-reactive protein;

Sample size*, n*=24. ^\*^*P*\<0.001, ^\*\*^*P*\<0.01, ^\*\*\*^*P*\<0.05.

###### Different linear regression analysis enter method considering Δ HOMA as the dependent variable and gender, liver lipid content, pancreas lipid content, VAT, or alternatively waist circumference, leptin and hs-CRP as independent variables

  *Variables entered in the models*   *Total R*^*2*^   *β coefficient*   t        *Significance*   F
  ----------------------------------- ---------------- ----------------- -------- ---------------- --------
  *1--- Gender*                       0.554            0.332             2.090    0.049            13.069
   Δ liver lipid content                               0.548             3.455    0.002             
  *2--- Gender*                       0.653            0.219             1.453    0.162            12.535
   Δ liver lipid content                               0.448             2.992    0.007             
   Δ waist circumference                               0.360             2.380    0.027             
  *3--- Gender*                       0.719            0.168             1.189    0.249            12.138
   Δ liver lipid content                               0.290             1.843    0.081             
   Δ waist circumference                               0.373             2.662    0.015             
   Δ Hs-CRP                                            0.313             2.110    0.048             
  *1--- Gender*                       0.554            0.332             2.090    0.049            13.069
   Δ liver lipid content                               0.548             3.455    0.002             
  *2--- Gender*                       0.585            0.242             1.944    0.066            9.408
   Δ liver lipid content                               0.412             2.857    0.010             
   Δ VAT                                               0.259             −0.162   0.873             
  *3--- Gender*                       0.629            0.227             1.346    0.194            8.062
   Δ liver lipid content                               0.320             1.624    0.121             
   Δ VAT                                               0.188             0.889    0.385             
   Δ Hs-CRP                                            0.262             1.502    0.150             
  *1--- Gender*                       0.497            0.343             2.011    0.057            10.390
   Δ waist circumference                               0.488             2.862    0.009             
  *1--- Gender*                       0.491            0.258             1.380    0.182            10.114
   Δ VAT                                               0.523             2.794    0.011             

Abbreviations: HOMA, homeostasis model assessment; hs-CRP, high-sensitivity C-reactive protein; VAT, visceral adipose tissue.
